In Q4 2020, sales increased 7% YoY to $123 million. Gross margin expanded by 110 basis points to 34.7%, leading to an EBITDA margin of 21.4%, up from 20.3% in Q4 2019. EPS grew by 16% to $0.43, continuing a positive trend set in the second half of 2020. Despite the impact of the pandemic, full-year sales only declined by 10%, with significant growth in industrial and defense end markets. The company remains focused on strategic growth investments, acquiring Sensor Scientific to expand its medical presence. In the first half of 2021, the temporary reinstatement of cost measures is expected to raise operating expenses, but the company anticipates delivering an EPS improvement of over $0.22 by the second half of 2022.